Inactive Instrument

Medivation Inc Stock

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2016	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
2016	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE

Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	16-10-28	RE
Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	16-09-07	RE
Abbott Laboratories : Medtech's 2016 stock surge confronts second-quarter test	16-07-08	RE
Medivation : Ex-Oppenheimer adviser arrested for trading on Pfizer employee's tips	16-06-03	RE
Medivation : sets eligibility date for shareholder consent on board revamp	16-06-02	RE
Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	16-05-25	RE
Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	16-05-25	RE
Exclusive: Sanofi to unveil challenge to Medivation's board - sources	16-05-25	RE
Astellas Pharma : Medivation succumbs to pressure to explore sale - sources	16-05-10	RE
Exclusive - Medivation succumbs to pressure to explore sale: sources	16-05-09	RE
Medivation : Sanofi ready to up offer for drugmaker Medivation, could oust board	16-05-05	RE
Medivation : Sanofi sees 'strong strategic' fit with U.S. Medivation	16-05-04	RE
Exclusive: Pfizer approaches Medivation about potential takeover - sources	16-05-03	RE
Medivation : Sanofi, Medivation dig in for big biotech takeover battle	16-04-29	RE
Medivation : Sanofi, Medivation dig in for big biotech takeover battle	16-04-29	RE

Medivation : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo	16-10-09	BU
Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	16-08-25	BU
Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information	16-08-22	BU
REMINDER: Medivation to Host Conference Call and Webcast Providing Detailed Review of Talazoparib on July 6, 2016	16-07-06	BU
Medivation : Enters into Confidentiality Agreements, Including with Sanofi	16-07-05	BU

Sanofi : relève ses prévisions pour 2016 et s'envole en Bourse	16-10-28
Sanofi : relève ses prévisions pour 2016 et veut céder ses activités génériques en Europe	16-10-28
Medivation : Neue, im Rahmen der ESMO 2016 präsentierte Ergebnisse belegen zusätzlich, dass XTANDITM▼ (Enzalutamid) die Zeit bis zur PSA-Progression bei fortgeschrittenem Prostatakarzinom im Vergleich zu Placebo signifikant verlängert	16-10-09
Medivation : De nouvelles données présentées au Congrès 2016 de l’ESMO démontrent une fois de plus que XTANDITM▼ (enzalutamide) améliore nettement, par rapport au placebo, le délai avant progression du PSA en cas de cancer de la prostate avancé	16-10-09
Sanofi : poursuit Merck en justice aux USA pour protéger les brevets de Lantus	16-09-19

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.50%	102B
REGENERON PHARMACEUTICALS, INC.	+2.01%	96.84B
ARGENX SE	-0.73%	21.48B
BIONTECH SE	-18.36%	20.82B
GENMAB A/S	-7.42%	18.6B
WUXI APPTEC CO., LTD.	-40.70%	16.81B
BEIGENE, LTD.	-26.41%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.81%	13.4B
SAREPTA THERAPEUTICS, INC.	+21.68%	11.06B